Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers.

Linares A, Assou S, Lapierre M, Thouennon E, Duraffourd C, Fromaget C, Boulahtouf A, Tian G, Ji J, Sahin O, Badia E, Boulle N, Cavaillès V.

Mol Oncol. 2019 Jul;13(7):1534-1547. doi: 10.1002/1878-0261.12505. Epub 2019 Jun 12.

2.

The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status.

Jeschke U, Zhang X, Kuhn C, Jalaguier S, Colinge J, Pfender K, Mayr D, Ditsch N, Harbeck N, Mahner S, Sixou S, Cavaillès V.

Int J Mol Sci. 2019 Feb 26;20(5). pii: E1016. doi: 10.3390/ijms20051016.

3.

Prognostic relevance of RIP140 and ERβ expression in unifocal versus multifocal breast cancers: a preliminary report.

Müller K, Sixou S, Kuhn C, Jalaguier S, Mayr D, Ditsch N, Weissenbacher T, Harbeck N, Mahner S, Cavaillès V, Jeschke U.

Int J Mol Sci. 2019 Jan 18;20(2). pii: E418. doi: 10.3390/ijms20020418.

4.

Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival.

Sixou S, Müller K, Jalaguier S, Kuhn C, Harbeck N, Mayr D, Engel J, Jeschke U, Ditsch N, Cavaillès V.

Transl Oncol. 2018 Oct;11(5):1090-1096. doi: 10.1016/j.tranon.2018.06.006. Epub 2018 Jul 11.

5.

RIP140 and LCoR expression in gastrointestinal cancers.

Triki M, Ben Ayed-Guerfali D, Saguem I, Charfi S, Ayedi L, Sellami-Boudawara T, Cavailles V, Mokdad-Gargouri R.

Oncotarget. 2017 Nov 25;8(67):111161-111175. doi: 10.18632/oncotarget.22686. eCollection 2017 Dec 19.

6.

Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer.

Vattai A, Cavailles V, Sixou S, Beyer S, Kuhn C, Peryanova M, Heidegger H, Hermelink K, Mayr D, Mahner S, Dannecker C, Jeschke U, Kost B.

Oncotarget. 2017 Oct 31;8(62):105356-105371. doi: 10.18632/oncotarget.22187. eCollection 2017 Dec 1.

7.

Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.

Voisin M, de Medina P, Mallinger A, Dalenc F, Huc-Claustre E, Leignadier J, Serhan N, Soules R, Ségala G, Mougel A, Noguer E, Mhamdi L, Bacquié E, Iuliano L, Zerbinati C, Lacroix-Triki M, Chaltiel L, Filleron T, Cavaillès V, Al Saati T, Rochaix P, Duprez-Paumier R, Franchet C, Ligat L, Lopez F, Record M, Poirot M, Silvente-Poirot S.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9346-E9355. doi: 10.1073/pnas.1707965114. Epub 2017 Oct 12.

8.

Design of Boron Nitride/Gelatin Electrospun Nanofibers for Bone Tissue Engineering.

Nagarajan S, Belaid H, Pochat-Bohatier C, Teyssier C, Iatsunskyi I, Coy E, Balme S, Cornu D, Miele P, Kalkura NS, Cavaillès V, Bechelany M.

ACS Appl Mater Interfaces. 2017 Oct 4;9(39):33695-33706. doi: 10.1021/acsami.7b13199. Epub 2017 Sep 21.

PMID:
28891632
9.

Expression and role of nuclear receptor coregulators in colorectal cancer.

Triki M, Lapierre M, Cavailles V, Mokdad-Gargouri R.

World J Gastroenterol. 2017 Jul 7;23(25):4480-4490. doi: 10.3748/wjg.v23.i25.4480. Review.

10.

Complex regulation of LCoR signaling in breast cancer cells.

Jalaguier S, Teyssier C, Nait Achour T, Lucas A, Bonnet S, Rodriguez C, Elarouci N, Lapierre M, Cavaillès V.

Oncogene. 2017 Aug 17;36(33):4790-4801. doi: 10.1038/onc.2017.97. Epub 2017 Apr 17.

11.

A Dominant Mutation in Nuclear Receptor Interacting Protein 1 Causes Urinary Tract Malformations via Dysregulation of Retinoic Acid Signaling.

Vivante A, Mann N, Yonath H, Weiss AC, Getwan M, Kaminski MM, Bohnenpoll T, Teyssier C, Chen J, Shril S, van der Ven AT, Ityel H, Schmidt JM, Widmeier E, Bauer SB, Sanna-Cherchi S, Gharavi AG, Lu W, Magen D, Shukrun R, Lifton RP, Tasic V, Stanescu HC, Cavaillès V, Kleta R, Anikster Y, Dekel B, Kispert A, Lienkamp SS, Hildebrandt F.

J Am Soc Nephrol. 2017 Aug;28(8):2364-2376. doi: 10.1681/ASN.2016060694. Epub 2017 Apr 5.

12.

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.

Lapierre M, Linares A, Dalvai M, Duraffourd C, Bonnet S, Boulahtouf A, Rodriguez C, Jalaguier S, Assou S, Orsetti B, Balaguer P, Maudelonde T, Blache P, Bystricky K, Boulle N, Cavaillès V.

Oncotarget. 2016 Apr 12;7(15):19693-708. doi: 10.18632/oncotarget.7564.

13.

Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds.

Delfosse V, Dendele B, Huet T, Grimaldi M, Boulahtouf A, Gerbal-Chaloin S, Beucher B, Roecklin D, Muller C, Rahmani R, Cavaillès V, Daujat-Chavanieu M, Vivat V, Pascussi JM, Balaguer P, Bourguet W.

Nat Commun. 2015 Sep 3;6:8089. doi: 10.1038/ncomms9089.

14.

Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line.

Badia E, Morena M, Lauret C, Boulahtouf A, Boulle N, Cavaillès V, Balaguer P, Cristol JP.

Breast Cancer. 2016 Sep;23(5):692-700. doi: 10.1007/s12282-015-0626-7. Epub 2015 Jul 21.

PMID:
26193841
15.

The emerging role of the transcriptional coregulator RIP140 in solid tumors.

Lapierre M, Docquier A, Castet-Nicolas A, Gitenay D, Jalaguier S, Teyssier C, Cavaillès V.

Biochim Biophys Acta. 2015 Aug;1856(1):144-50. doi: 10.1016/j.bbcan.2015.06.006. Epub 2015 Jun 25. Review.

PMID:
26116758
16.

Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia.

Lapierre M, Castet-Nicolas A, Gitenay D, Jalaguier S, Teyssier C, Bret C, Cartron G, Moreaux J, Cavaillès V.

J Hematol Oncol. 2015 Mar 4;8:20. doi: 10.1186/s13045-015-0116-6. Review.

17.

Research Resource: STR DNA profile and gene expression comparisons of human BG-1 cells and a BG-1/MCF-7 clonal variant.

Li Y, Arao Y, Hall JM, Burkett S, Liu L, Gerrish K, Cavailles V, Korach KS.

Mol Endocrinol. 2014 Dec;28(12):2072-81. doi: 10.1210/me.2014-1229.

18.

Structural and functional profiling of environmental ligands for estrogen receptors.

Delfosse V, Grimaldi M, Cavaillès V, Balaguer P, Bourguet W.

Environ Health Perspect. 2014 Dec;122(12):1306-13. doi: 10.1289/ehp.1408453. Epub 2014 Sep 26.

19.

Selectivity of natural, synthetic and environmental estrogens for zebrafish estrogen receptors.

Pinto C, Grimaldi M, Boulahtouf A, Pakdel F, Brion F, Aït-Aïssa S, Cavaillès V, Bourguet W, Gustafsson JA, Bondesson M, Balaguer P.

Toxicol Appl Pharmacol. 2014 Oct 1;280(1):60-9. doi: 10.1016/j.taap.2014.07.020. Epub 2014 Aug 8.

20.

Regulation of intestinal homeostasis and tumorigenesis by the transcriptional coregulator RIP140.

Cavaillès V, Lapierre M.

Mol Cell Oncol. 2014 Oct 31;1(2):e960761. doi: 10.4161/23723548.2014.960761. eCollection 2014 Apr-Jun.

21.

RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis.

Lapierre M, Bonnet S, Bascoul-Mollevi C, Ait-Arsa I, Jalaguier S, Del Rio M, Plateroti M, Roepman P, Ychou M, Pannequin J, Hollande F, Parker M, Cavailles V.

J Clin Invest. 2014 May;124(5):1899-913. doi: 10.1172/JCI65178. Epub 2014 Mar 25.

22.

Transcriptional repression of estrogen receptor α signaling by SENP2 in breast cancer cells.

Nait Achour T, Sentis S, Teyssier C, Philippat A, Lucas A, Corbo L, Cavaillès V, Jalaguier S.

Mol Endocrinol. 2014 Feb;28(2):183-96. doi: 10.1210/me.2013-1376. Epub 2013 Jan 1.

23.

[The Warburg effect: from theory to therapeutic applications in cancer].

Razungles J, Cavaillès V, Jalaguier S, Teyssier C.

Med Sci (Paris). 2013 Nov;29(11):1026-33. doi: 10.1051/medsci/20132911020. Epub 2013 Nov 20. Review. French.

24.

Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.

Cázares Marinero Jde J, Lapierre M, Cavaillès V, Saint-Fort R, Vessières A, Top S, Jaouen G.

Dalton Trans. 2013 Nov 21;42(43):15489-501. doi: 10.1039/c3dt51917a.

PMID:
24030275
25.

Negative regulation of estrogen signaling by ERβ and RIP140 in ovarian cancer cells.

Docquier A, Garcia A, Savatier J, Boulahtouf A, Bonnet S, Bellet V, Busson M, Margeat E, Jalaguier S, Royer C, Balaguer P, Cavaillès V.

Mol Endocrinol. 2013 Sep;27(9):1429-41. doi: 10.1210/me.2012-1351. Epub 2013 Jul 24.

26.

Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes.

Delfosse V, Grimaldi M, Pons JL, Boulahtouf A, le Maire A, Cavailles V, Labesse G, Bourguet W, Balaguer P.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14930-5. doi: 10.1073/pnas.1203574109. Epub 2012 Aug 27.

27.

Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells.

Badia E, Docquier A, Busson M, Lapierre M, Pujol P, Balaguer P, Cavailles V.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):176-85. doi: 10.1016/j.jsbmb.2012.05.006. Epub 2012 May 29.

28.

The RIP140 gene is a transcriptional target of E2F1.

Docquier A, Augereau P, Lapierre M, Harmand PO, Badia E, Annicotte JS, Fajas L, Cavaillès V.

PLoS One. 2012;7(5):e35839. doi: 10.1371/journal.pone.0035839. Epub 2012 May 18.

29.

Occurrence of androgens in sewage treatment plants influents is associated with antagonist activities on other steroid receptors.

Bellet V, Hernandez-Raquet G, Dagnino S, Seree L, Pardon P, Bancon-Montiny C, Fenet H, Creusot N, Aït-Aïssa S, Cavailles V, Budzinski H, Antignac JP, Balaguer P.

Water Res. 2012 Apr 15;46(6):1912-22. doi: 10.1016/j.watres.2012.01.013. Epub 2012 Jan 25.

PMID:
22325933
30.

Affinity purification using recombinant PXR as a tool to characterize environmental ligands.

Dagnino S, Bellet V, Grimaldi M, Riu A, Aït-Aïssa S, Cavaillès V, Fenet H, Balaguer P.

Environ Toxicol. 2014 Feb;29(2):207-15. doi: 10.1002/tox.20787. Epub 2012 Jan 5.

PMID:
22223399
31.

[Vitamin B6 and cancer: from clinical data to molecularly mechanisms].

Sujol G, Docquier A, Boulahtouf A, Castet-Nicolas A, Cavaillès V.

Bull Cancer. 2011 Oct;98(10):1201-8. doi: 10.1684/bdc.2011.1458. Review. French.

32.

Cognitive impairments in adult mice with constitutive inactivation of RIP140 gene expression.

Duclot F, Lapierre M, Fritsch S, White R, Parker MG, Maurice T, Cavaillès V.

Genes Brain Behav. 2012 Feb;11(1):69-78. doi: 10.1111/j.1601-183X.2011.00731.x. Epub 2011 Oct 19.

33.

Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer.

Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, Duong V, Gleizes M, Thénot S, Bibeau F, Theillet C, Cavaillès V.

Am J Pathol. 2011 Apr;178(4):1461-9. doi: 10.1016/j.ajpath.2010.12.026.

34.

Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?

Linares A, Dalenc F, Balaguer P, Boulle N, Cavailles V.

J Biomed Biotechnol. 2011;2011:856985. doi: 10.1155/2011/856985. Epub 2010 Dec 6. Review.

35.

The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes.

Docquier A, Harmand PO, Fritsch S, Chanrion M, Darbon JM, Cavaillès V.

Clin Cancer Res. 2010 Jun 1;16(11):2959-70. doi: 10.1158/1078-0432.CCR-09-3153. Epub 2010 Apr 21.

36.

The steroid receptor RNA activator protein is recruited to promoter regions and acts as a transcriptional repressor.

Chooniedass-Kothari S, Hamedani MK, Auge C, Wang X, Carascossa S, Yan Y, Cooper C, Vincett D, Myal Y, Jalaguier S, Cavailles V, Leygue E.

FEBS Lett. 2010 Jun 3;584(11):2218-24. doi: 10.1016/j.febslet.2010.04.022. Epub 2010 Apr 14.

37.

Estrogenic and AhR activities in dissolved phase and suspended solids from wastewater treatment plants.

Dagnino S, Gomez E, Picot B, Cavaillès V, Casellas C, Balaguer P, Fenet H.

Sci Total Environ. 2010 May 15;408(12):2608-15. doi: 10.1016/j.scitotenv.2010.02.034. Epub 2010 Mar 19.

PMID:
20303573
38.

Estrogen receptor interactions and dynamics monitored in live cells by fluorescence cross-correlation spectroscopy.

Savatier J, Jalaguier S, Ferguson ML, Cavaillès V, Royer CA.

Biochemistry. 2010 Feb 2;49(4):772-81. doi: 10.1021/bi9013006.

PMID:
20039662
39.

Biological analysis of endocrine-disrupting compounds in Tunisian sewage treatment plants.

Mnif W, Dagnino S, Escande A, Pillon A, Fenet H, Gomez E, Casellas C, Duchesne MJ, Hernandez-Raquet G, Cavaillès V, Balaguer P, Bartegi A.

Arch Environ Contam Toxicol. 2010 Jul;59(1):1-12. doi: 10.1007/s00244-009-9438-0. Epub 2009 Dec 22.

PMID:
20033144
40.

Protein arginine methylation in estrogen signaling and estrogen-related cancers.

Teyssier C, Le Romancer M, Sentis S, Jalaguier S, Corbo L, Cavaillès V.

Trends Endocrinol Metab. 2010 Mar;21(3):181-9. doi: 10.1016/j.tem.2009.11.002. Epub 2009 Dec 11. Review.

41.

New stably transfected bioluminescent cells expressing FLAG epitope-tagged estrogen receptors to study their chromatin recruitment.

Badia E, Escande A, Balaguer P, Métivier R, Cavailles V.

BMC Biotechnol. 2009 Sep 9;9:77. doi: 10.1186/1472-6750-9-77.

42.

A new mechanism of SOX9 action to regulate PKCalpha expression in the intestine epithelium.

Dupasquier S, Abdel-Samad R, Glazer RI, Bastide P, Jay P, Joubert D, Cavaillès V, Blache P, Quittau-Prévostel C.

J Cell Sci. 2009 Jul 1;122(Pt 13):2191-6. doi: 10.1242/jcs.036483. Epub 2009 Jun 9.

43.

Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites.

Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavaillès V, Balaguer P, Maudelonde T.

J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):8-14. doi: 10.1016/j.jsbmb.2009.03.008. Epub 2009 Apr 2.

44.

Specific activity of class II histone deacetylases in human breast cancer cells.

Duong V, Bret C, Altucci L, Mai A, Duraffourd C, Loubersac J, Harmand PO, Bonnet S, Valente S, Maudelonde T, Cavailles V, Boulle N.

Mol Cancer Res. 2008 Dec;6(12):1908-19. doi: 10.1158/1541-7786.MCR-08-0299.

45.

Profiling of benzophenone derivatives using fish and human estrogen receptor-specific in vitro bioassays.

Molina-Molina JM, Escande A, Pillon A, Gomez E, Pakdel F, Cavaillès V, Olea N, Aït-Aïssa S, Balaguer P.

Toxicol Appl Pharmacol. 2008 Nov 1;232(3):384-95. doi: 10.1016/j.taap.2008.07.017. Epub 2008 Jul 29.

46.

Regulation of hormone signaling by nuclear receptor interacting proteins.

Duong V, Augereau P, Badia E, Jalaguier S, Cavailles V.

Adv Exp Med Biol. 2008;617:121-7. doi: 10.1007/978-0-387-69080-3_11. Review. No abstract available.

47.

Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

Badia E, Oliva J, Balaguer P, Cavaillès V.

Curr Med Chem. 2007;14(28):3035-45. Review.

48.

Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents.

Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, Cavaillès V.

Cancer Res. 2007 Jun 1;67(11):5513-21.

49.

Estrogens and antiestrogens activate hPXR.

Mnif W, Pascussi JM, Pillon A, Escande A, Bartegi A, Nicolas JC, Cavaillès V, Duchesne MJ, Balaguer P.

Toxicol Lett. 2007 Apr 5;170(1):19-29. Epub 2007 Feb 16.

PMID:
17379461
50.

International Union of Pharmacology. LXIV. Estrogen receptors.

Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA.

Pharmacol Rev. 2006 Dec;58(4):773-81. Review. No abstract available.

PMID:
17132854

Supplemental Content

Loading ...
Support Center